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Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128 S111graft-versus host disease (GVHD) prophylaxis. The primary
objective was to test the non-inferiority of overall survival
after IV BU compared to TBI. From March 2009 to February
2011,1,483eligiblepatientswereenrolled (IVBU,n¼1025, TBI,
n¼458) from 120 transplant centers. The 2 cohorts were
similar with respect to median age (45 years), gender (50%
female), race (88% Caucasian), performance status (68%90),
and HCT-CI. Most patients had acute myeloid leukemia (68%
BU, 78% TBI). Disease status was early (51%), intermediate
(18%) and advanced (31%) andwere balanced in both cohorts.
Grafts were primarily PB (77%) frommatched sibling (40%) or
well-matched unrelated donors (48%), balanced in both
cohorts. IVBUregimenswereCY (59%) or Flu (41%) based. 2-yr
probabilities of overall survival (95% CI), were 56% (53-60%)
and 48% (43-54%) for IV BU and TBI, respectively (p¼0.02).
Corresponding probabilities of progression-free survival
(PFS) were 49% (45-52%) and 44% (40-49%), (p¼0.17). The
incidence of hepatic veno-occlusive disease (VOD)/sinusoidal
obstruction syndrome (SOS)was5% forBUand1% for TBI; (p<
0.001). Outcomes were the same for BUþCY and BUþFlu
regimens. There were no differences in engraftment of
neutrophils or platelets, disease relapse, grade 2-4 acute or
chronic GVHD. Multivariate Analysis (MVA) (adjusting for
HCT-CI, disease andstatus, donor type, age, PS, and race) of the
main outcomes is summarized in Table. Compared to TBI, IV
BU was associated with superior survival and no increased
risk of relapse or TRM. These results support the use of mye-
loablative BU- over TBI-based conditioning regimens for
treatment of AML, MDS, and CML.
Table
Cox Proportional Hazards MVA for IV BU vs. TBI
Outcome N IV BU vs. TBI
HR (95% CI)
P-value
OM 1439 0.82 (0.68-0.98) 0.026
TRM 1434 0.81 (0.61-1.08) 0.15
Rel 1434 0.93 (0.76-1.12) 0.43
TF 1434 0.90 (0.77-1.06) 0.19
HR indicats hazard ratio; N, number of subjects; OM, overall mortality; Rel,
relapse; TF, treatment failure, relapse or death; TRM, treatment-related5
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We have previously demonstrated that small numbers of
ex vivo-expanded, trivirus-speciﬁc Tcells targeting EBV, CMV,
and Adv are safe, effective and protective in vivo. However,
broader implementation is limited by the need for infectious
virus/vector, and prolonged (8-12wks) and complex manu-
facture, while antigenic competition limits extension to
additional viruses. We now evaluate whether T-cell lines
manufactured using methods that exclude viral components
and utilize simpliﬁed manufacturing technology can be clin-
ically effective. With NHLBI-PACT support, 29 clinical-grade
rCTL lines have beengenerated. Froman initial 15x106 PBMCs,
mortality.we prepared a median of 21488x106 T-cells (range 100-
420x106) over 9-11 days using DCs nucleofected with DNA
plasmids encoding immunogenic EBV (LMP2, EBNA1 and
BZLF1), Adv (Hexon and Penton), and CMV (pp65 and IE1)
antigens, and expansion with IL4þ7 in G-Rex devices. The
rCTL lines were polyclonal, comprising both CD4þ (333%)
and CD8þ (60.53%) cells, that expressed activation and
memory markers. Twenty lines generated from donors that
wereseropositive for all virusesdemonstratedactivityagainst
all 3 targets - CMV (IE1: 359100; pp65: 637177SFC/2x105),
EBV (LMP2: 21760, EBNA1: 6719 and BZLF1: 11131) and
Adv (Hexon: 26574, Penton: 19153) - while 9 lines
generated from CMV seronegative donors demonstrated
activity exclusively against EBV (LMP2: 19770, EBNA1:
14551 and BZLF1: 23984) and Adv (Hexon: 27196, Pen-
ton: 25490). None of the T-cell lines reacted against
unmodiﬁed recipient cells. To date we have administered
these lines to 10 allogeneic HSCT recipients at doses ranging
from 0.5-2x107/m2 as treatment for CMV (n¼3), Adv (n¼2),
EBV (n¼2), EBVþAdv (n¼1), and CMVþAdv (n¼2). One
patient developed a skin rash 2weeks post-rCTLs but no other
toxicity have been observed. Eight treated patients, including
one with a biopsy-proven EBV lymphoma and the 3 patients
with double reactivations, had complete clinical responses to
rCTL, which corresponded with an increase in the frequency
of virus-speciﬁc T-cells detected in peripheral blood. For CMV
we saw an increase from a median of 0.5 to 96 and 1 to 277
SFC/4x105 IE1 and pp65-speciﬁc T cells, respectively 3-6wks
post-infusion; for Adv an increase from mean 0.5 to 137 and
0.5 to 99 SFC/4x105 Hexon and Penton-speciﬁc cells, respec-
tively, and for EBV an increase from 2.8 to 227,1.5 to 39, and 1
to 188.5 SFC/4x105 EBNA1, LMP2, and BZLF1-speciﬁc T-cells,
respectively. Twopatients failed to respond to rCTLs; onewith
a 3 year history of persistent CMV colitis and one with
elevated EBV DNA; both had high pre-existing virus-speciﬁc
T-cell precursors. rCTLs have been safe and effective in 80% of
treated patients and have the potential to increase the avail-
ability of cell products for HSCT recipients. We are currently
extending this platform to additional viruses.
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Idiopathic pneumonia syndrome (IPS) is a noninfectious
pulmonary disorder occurring acutely post-SCT, associated
